Cargando…

Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer

BACKGROUND: This paper describes the testicular cancer trends for incidence, survival, socio-economic status (SES) disparities and second cancer occurrence in Geneva, Switzerland, a high-risk population. METHODS: We included all testicular germ-cell tumors recorded in the population-based Geneva can...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaffar, Robin, Pant, Samaksha, Bouchardy, Christine, Schubert, Hyma, Rapiti, Elisabetta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621969/
https://www.ncbi.nlm.nih.gov/pubmed/31291913
http://dx.doi.org/10.1186/s12894-019-0494-0
_version_ 1783434142412701696
author Schaffar, Robin
Pant, Samaksha
Bouchardy, Christine
Schubert, Hyma
Rapiti, Elisabetta
author_facet Schaffar, Robin
Pant, Samaksha
Bouchardy, Christine
Schubert, Hyma
Rapiti, Elisabetta
author_sort Schaffar, Robin
collection PubMed
description BACKGROUND: This paper describes the testicular cancer trends for incidence, survival, socio-economic status (SES) disparities and second cancer occurrence in Geneva, Switzerland, a high-risk population. METHODS: We included all testicular germ-cell tumors recorded in the population-based Geneva cancer registry during the period 1970–2012. Changes in incidence trends were assessed using Joinpoint regression to calculate the annual percentage change (APC). Overall and cancer-specific survivals (OS, CSS) were estimated by Kaplan Meyer methods. To evaluate the risk of a second cancer we calculated the Standardized Incidence Ratios (SIR) using the Geneva population incidence rates. RESULTS: The average annual testicular cancer rate was 7.32/100 000 men, with a non-significant increasing trend during the study period. The highest rates were observed among men younger than 39 years. Despite a trend toward earlier diagnosis, 14% of patients were diagnosed at a late stage. Patients with non-seminoma tumours and patients with low SES were more often diagnosed with an advanced stage. Both OS and CSS improved during the study period but with strong differences by age, stage, morphology and SES. The risk for developing a second cancer was more than doubled. This risk was particularly high for a contralateral testicular cancer, bladder cancer and pancreatic cancer. CONCLUSIONS: Overall, there was no substantial increase in the incidence of testicular cancer in Geneva in recent decades, however the prognosis has improved. The high risk of developing a second cancer, the differences in stage at diagnosis and survival by SES, require enhanced awareness and surveillance by clinicians, patients and men in general.
format Online
Article
Text
id pubmed-6621969
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66219692019-07-22 Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer Schaffar, Robin Pant, Samaksha Bouchardy, Christine Schubert, Hyma Rapiti, Elisabetta BMC Urol Research Article BACKGROUND: This paper describes the testicular cancer trends for incidence, survival, socio-economic status (SES) disparities and second cancer occurrence in Geneva, Switzerland, a high-risk population. METHODS: We included all testicular germ-cell tumors recorded in the population-based Geneva cancer registry during the period 1970–2012. Changes in incidence trends were assessed using Joinpoint regression to calculate the annual percentage change (APC). Overall and cancer-specific survivals (OS, CSS) were estimated by Kaplan Meyer methods. To evaluate the risk of a second cancer we calculated the Standardized Incidence Ratios (SIR) using the Geneva population incidence rates. RESULTS: The average annual testicular cancer rate was 7.32/100 000 men, with a non-significant increasing trend during the study period. The highest rates were observed among men younger than 39 years. Despite a trend toward earlier diagnosis, 14% of patients were diagnosed at a late stage. Patients with non-seminoma tumours and patients with low SES were more often diagnosed with an advanced stage. Both OS and CSS improved during the study period but with strong differences by age, stage, morphology and SES. The risk for developing a second cancer was more than doubled. This risk was particularly high for a contralateral testicular cancer, bladder cancer and pancreatic cancer. CONCLUSIONS: Overall, there was no substantial increase in the incidence of testicular cancer in Geneva in recent decades, however the prognosis has improved. The high risk of developing a second cancer, the differences in stage at diagnosis and survival by SES, require enhanced awareness and surveillance by clinicians, patients and men in general. BioMed Central 2019-07-10 /pmc/articles/PMC6621969/ /pubmed/31291913 http://dx.doi.org/10.1186/s12894-019-0494-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Schaffar, Robin
Pant, Samaksha
Bouchardy, Christine
Schubert, Hyma
Rapiti, Elisabetta
Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title_full Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title_fullStr Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title_full_unstemmed Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title_short Testicular cancer in Geneva, Switzerland, 1970–2012: incidence trends, survival and risk of second cancer
title_sort testicular cancer in geneva, switzerland, 1970–2012: incidence trends, survival and risk of second cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621969/
https://www.ncbi.nlm.nih.gov/pubmed/31291913
http://dx.doi.org/10.1186/s12894-019-0494-0
work_keys_str_mv AT schaffarrobin testicularcanceringenevaswitzerland19702012incidencetrendssurvivalandriskofsecondcancer
AT pantsamaksha testicularcanceringenevaswitzerland19702012incidencetrendssurvivalandriskofsecondcancer
AT bouchardychristine testicularcanceringenevaswitzerland19702012incidencetrendssurvivalandriskofsecondcancer
AT schuberthyma testicularcanceringenevaswitzerland19702012incidencetrendssurvivalandriskofsecondcancer
AT rapitielisabetta testicularcanceringenevaswitzerland19702012incidencetrendssurvivalandriskofsecondcancer